Patients with soft tissue sarcoma experienced a confirmed clinical response following treatment with a targeted therapy, according to a recent study. READ MORE
Health-related quality of life and its impact on disease progression should be a consideration when selecting treatment for sarcoma.
Patients with soft tissue sarcoma experienced a confirmed clinical response following treatment with a targeted therapy, according to a recent study.
Young patients with head and neck sarcoma treated with proton beam therapy had similar outcomes with less of an impact on quality of life as those treated with traditional photon radiation.
The best potential strategy involving tyrosine kinase inhibitors for the treatment of gastrointestinal stromal tumors has been identified.
Kaposi Sarcoma (KS) skin lesions are more likely to respond to local external beam radiotherapy than repeat radiotherapy.
Research in Review
Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors, supporting efforts for further research.
Neoadjuvant chemotherapy with epirubicin plus ifosfamide improves outcomes in patients with soft tissue sarcoma who are at high-risk of recurrence.
Results argue against the inclusion of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma.